INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH AND INNOVATIVE STUDIES
ISSN: 2820-7157
www.ijsrisjournal.com

August 2024 **Volume 3** **Number 4** **158-160**

Received Date: July 08, 2024 **Accepted Date:** July 29, 2024 **Published Date:** August 01, 2024

Available Online at https://www.ijsrisjournal.com/index.php/ojsfiles/article/view/304

https://doi.org/10.5281/zenodo.14610813

Chlamydia Positivity in Women Screened in Family Planning Clinics: A Comprehensive Review

Anhar Abdullah Alsadiq [1,] Reem Mirza Alsarnoukh[2], Maher Abdulaziz Alhmud[3], Omayma ALI ALNAKHLI[2], Ehab ali alnakli[4], Asma Ali alnakhli[5], Faten Ahmed Almubarak [6], Tawah Mohammad aloffi[6], Kawther Abdullah bohassan[6], SAEED ALI BOHALG[7], Nasser yousef ALkhalifah[7], Abdullah Mohammed Al Abdullah[7], Mohammed hassan Alshorime[3], Montaha Ahmed Al Nemer[8], Wafa Ahmed Al Nemer[8]

1.Safwa General Hospital
2.Maternity & Children Hospital - MCH
3.Rehabilitation hospital
4. Medical Rehabilitation Hospital
5.Alsalam endowment hospital
6.king fahad hospital in hofuf
7.Sheih Hassan ALAfaleq Long-term Care Hospital
8.King Fahad Specialist Hospital

ABSTRACT

Chlamydia trachomatis is one of the most prevalent sexually transmitted infections (STIs) globally, with significant implications for women's reproductive health. Screening for Chlamydia in family planning clinics is critical for early detection and prevention of adverse outcomes such as pelvic inflammatory disease, infertility, and ectopic pregnancy. This review explores the prevalence of Chlamydia positivity among women screened in family planning clinics, the associated risk factors, and the role of targeted screening interventions. Current challenges in screening implementation and strategies to improve detection and treatment outcomes are also discussed.

Introduction

Chlamydia trachomatis infection, a sexually transmitted disease associated with serious adverse outcomes among women, including pelvic inflammatory disease, ectopic pregnancy, tubal-factor infertility, and chronic pelvic pain, is the most commonly reported nationally notifiable disease in the United States[1,2]. Over 1.2 million cases were reported to the Centers for Disease Control and Prevention from state and local health departments in 2008[3]. However, an estimated 2.8 million chlamydia cases occur annually, suggesting that under-detection of cases is substantial[4].

Early identification and treatment of Chlamydia infections are essential to prevent complications, reduce transmission, and promote reproductive health. This review aims to examine the prevalence and trends of Chlamydia positivity in women screened in family planning clinics, as well as the factors influencing screening uptake and outcomes.

1. Prevalence of Chlamydia Positivity in Family Planning Clinics

The reported prevalence of Chlamydia positivity among women attending family planning clinics varies by region, population demographics, and screening methodologies. Studies have indicated that young women aged 15–24 years are at the highest risk. For instance:

- **United States**: According to the Centers for Disease Control and Prevention [5], Chlamydia positivity rates among women screened in family planning clinics ranged from 6% to 15%, with higher rates in adolescents and minority populations.
- **United Kingdom**: The National Chlamydia Screening Programme reported a positivity rate of 7% among women under 25 screened in sexual health and family planning clinics (Public Health England, 2021).
- **Developing Countries**: Prevalence rates are often higher, ranging from 10% to 20%, due to limited access to screening and education programs.

2. Risk Factors for Chlamydia Positivity

Several factors contribute to increased Chlamydia positivity rates among women in family planning clinics:

- **Age**: Women aged 15–24 are most at risk due to biological susceptibility and higher rates of unprotected sex.
- **Multiple Sexual Partners**: Increased number of sexual partners correlates with higher risk.
- **Contraceptive Use**: Barrier contraceptives reduce the risk, while hormonal methods alone may not protect against STIs.
- **Socioeconomic Status**: Limited access to healthcare and sexual health education increases susceptibility.
- **History of STIs**: Previous infections are associated with a higher likelihood of reinfection

3. Challenges in Screening and Detection

- **Asymptomatic Nature of Chlamydia**: Up to 70% of women with Chlamydia infections are asymptomatic, leading to underdiagnosis [6,7].
- **Stigma**: Social stigma surrounding STIs can deter women from seeking screening services.
- **Limited Resources**: In low-income settings, family planning clinics often lack the resources for widespread screening.
- **Follow-up and Partner Notification**: Ensuring treatment compliance and partner notification remains a challenge.

4. Strategies to Improve Screening and Outcomes

- **Targeted Screening**: Prioritizing high-risk groups, such as sexually active women under 25, can improve efficiency and cost-effectiveness.
- **Rapid Testing**: Point-of-care testing enables same-day diagnosis and treatment, reducing the likelihood of loss to follow-up.
- **Education Campaigns**: Increasing awareness about Chlamydia and the importance of screening can reduce stigma and encourage participation.
- **Integrated Services**: Combining STI screening with routine family planning services ensures higher coverage and accessibility.
- **Digital Health Tools**: Mobile apps and telehealth platforms can facilitate patient education, appointment scheduling, and follow-up reminders.

5. Future Directions

Advancements in diagnostic technologies, such as molecular point-of-care testing, hold promise for expanding Chlamydia screening in family planning clinics. Additionally, policy efforts to integrate STI prevention and reproductive health services can further enhance care delivery. Research is also needed to evaluate the long-term impact of screening programs on reducing Chlamydia prevalence and associated complications.

Conclusion

Screening for Chlamydia in family planning clinics is a critical intervention for protecting women's reproductive health. While significant progress has been made, challenges such as stigma, resource limitations, and asymptomatic infections persist. By adopting targeted screening strategies, leveraging technology, and enhancing education efforts, family planning clinics can play a pivotal role in reducing the burden of Chlamydia and improving health outcomes for women.

References

1.Adams DA, Jajosky RA, Ajani U, Kriseman J, Sharp P, Onwen DH, et al. Summary of notifiable diseases--United States, 2012. MMWR Morb Mortal Wkly Rep 2014;61.
2.Geisler WM, Hocking JS, Darville T, Batteiger BE, Brunham RC. Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clinical Infectious Diseases 2022;74. https://doi.org/10.1093/cid/ciac126.
3.Dong Y, Wang L, Burgner DP, Miller JE, Song Y, Ren X, et al. Infectious diseases in children and adolescents in China: Analysis of national surveillance data from 2008 to 2017. The BMJ 2020;369. https://doi.org/10.1136/bmj.m1043.
4.Weinstock H, Berman S, Cates W. Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000. Perspect Sex Reprod Health 2004;36. https://doi.org/10.1363/3600604.
5.Centers for Disease Control and Prevention. Preliminary 2021 STD Surveillance Data. Centers for Disease Control and Prevention 2022.
6.Malhotra M, Sood S, Mukherjee A, Muralidhar S, Bala M. Genital Chlamydia trachomatis: An update. Indian Journal of Medical Research 2013;138.
7.Derrick TR, Sandetskaya N, Pickering H, Kölsch A, Ramadhani A, Mafuru E, et al. DjinniChip: evaluation of a novel molecular rapid diagnostic device for the detection of Chlamydia trachomatis in trachoma-endemic areas. Parasit Vectors 2020;13. https://doi.org/10.1186/s13071-020-04414-6.